Wegovy sales double to boost Novo Nordisk's 4th quarter
Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...
Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback